Stock Detail
MANNKIND CORPORATION
Sector: Biotechnology
Latest Quote @ Thu May 5 08:55:16 (15 min delayed)
| $6.42 |
$6.43 |
$6.23 |
+0.87 |
16.23% |
23.37M |
Last Day's Data
| $6.23 |
$6.54 |
$0.87 |
16.23% |
0.00 |
$5.36 |
| $5.54 |
$5.51 |
2.00 |
1.78B |
4.67M |
0.00 |
Pivot Table
| R2 |
R1 |
Pivot |
S1 |
S2 |
| 7.12 |
6.67 |
6.09 |
5.64 |
5.06 |
Stock Profile
MannKind Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for diseases, such as diabetes and cancer. It commenced phase three clinical trials in Europe of its lead product, the Technosphere insulin system, to treat diabetes. This therapy consists of a dry powder Technosphere formulation of insulin that is inhaled into the deep lung using MedTone inhaler. Its technology is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded. The company was incorporated in 1991 as Pharmaceutical Discovery Corporation and changed its name to MannKind Corporation in 2001. MannKind Corporation is headquartered in Valencia, California.
